CD274 and non-small cell lung carcinoma: In 2018, Niemeijer et al. [195] studied 13 patients with advanced NSCLC before treatment with nivolumab using two new immuno-PET radiotracers: an anti-PD-1 radiotracer, [89Zr]nivolumab (images acquired after 7 days after injection), and an anti-PD-L1 radiotracer, [18F]labeled anti-PD-L1 fibronectin-based protein (adnectin), namely [18F]BMS-986192 (images acquired after 1 h after injection).